We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate. It delivered an average earnings surprise of -9.34% in the past four quarters. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
XRAY’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $851.6 million. The consensus mark for earnings is pinned at 29 cents per share.
Factors to Note Ahead of XRAY’s Q1 Results
A significant factor to monitor in XRAY’s first-quarter 2025 results is the ongoing impact of the Byte business wind-down. In the fourth quarter of 2024, Byte contributed to a $62 million year-over-year decline in sales, prompting a major non-cash goodwill impairment of $370 million. This voluntary exit from the direct-to-consumer aligner segment signals a strategic shift toward more sustainable, clinician-directed models such as SureSmile. As the company executes its plan to fully exit Byte by mid-2025, investors will be keen to assess how much of the negative revenue drag from Byte persists into the first quarter and whether any early benefits of resource reallocation toward high-margin segments begin to emerge.
The U.S. region saw a significant 29.9% decline in year-over-year sales in the fourth quarter of 2024, driven by Byte’s exit, underperformance in the CAD/CAM segment, and unfavorable distributor ordering patterns. Management acknowledged challenges in aligning demand forecasting with partner inventory levels. Heading into the first quarter of 2025, investors are likely to closely watch for signs of stabilization or rebound in U.S. demand, particularly in procedural categories like implants and endodontics.
Despite overall revenue pressure, XRAY's SureSmile and imaging categories stood out in the fourth quarter, with SureSmile delivering more than 20% growth in Europe and imaging growing nearly 13% globally. These segments are central to the company’s digital dentistry narrative and reflect strong clinician adoption. In the first quarter of 2025, investors might have looked for sustained momentum in these higher-margin, tech-enabled product lines.
In the fourth quarter of 2024, DENTSPLY SIRONAunderscored its commitment to advancing digital dentistry through the launch and expansion of key products that are expected to gain further traction in first-quarter 2025. The company introduced PrimeScan 2, an upgraded version of its intraoral scanner, which features enhanced speed, usability, and accuracy, designed to improve both the clinical experience and workflow integration.
Another notable development was the European launch of the MIS LYNX implant system under the MIS brand, which received strong initial feedback from clinicians. Additionally, DENTSPLY SIRONAcontinued rolling out DS Core, its digital cloud platform that integrates diagnostics, imaging, and treatment planning across devices. As the first quarter unfolds, investors' focus will be on the early commercial performance of these technologies and how they support procedural growth, particularly in restorative and implant dentistry.
Our proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
XRAY’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -4.92%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
ANIP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.32%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 30.6% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.82% and a Zacks Rank #2. The company is slated to release first-quarter fiscal 2025 results on May 7.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 4.94%. The Zacks Consensus Estimate for COR’s fiscal first-quarter EPS is expected to rise 7.1% from the year-ago reported figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.37% and a Zacks Rank #3. The company is slated to release first-quarter 2025 results on May 7.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 54.58%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release first-quarter 2025 results on May 8, before the opening bell.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate. It delivered an average earnings surprise of -9.34% in the past four quarters. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
XRAY’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $851.6 million. The consensus mark for earnings is pinned at 29 cents per share.
Factors to Note Ahead of XRAY’s Q1 Results
A significant factor to monitor in XRAY’s first-quarter 2025 results is the ongoing impact of the Byte business wind-down. In the fourth quarter of 2024, Byte contributed to a $62 million year-over-year decline in sales, prompting a major non-cash goodwill impairment of $370 million. This voluntary exit from the direct-to-consumer aligner segment signals a strategic shift toward more sustainable, clinician-directed models such as SureSmile. As the company executes its plan to fully exit Byte by mid-2025, investors will be keen to assess how much of the negative revenue drag from Byte persists into the first quarter and whether any early benefits of resource reallocation toward high-margin segments begin to emerge.
The U.S. region saw a significant 29.9% decline in year-over-year sales in the fourth quarter of 2024, driven by Byte’s exit, underperformance in the CAD/CAM segment, and unfavorable distributor ordering patterns. Management acknowledged challenges in aligning demand forecasting with partner inventory levels. Heading into the first quarter of 2025, investors are likely to closely watch for signs of stabilization or rebound in U.S. demand, particularly in procedural categories like implants and endodontics.
Despite overall revenue pressure, XRAY's SureSmile and imaging categories stood out in the fourth quarter, with SureSmile delivering more than 20% growth in Europe and imaging growing nearly 13% globally. These segments are central to the company’s digital dentistry narrative and reflect strong clinician adoption. In the first quarter of 2025, investors might have looked for sustained momentum in these higher-margin, tech-enabled product lines.
In the fourth quarter of 2024, DENTSPLY SIRONAunderscored its commitment to advancing digital dentistry through the launch and expansion of key products that are expected to gain further traction in first-quarter 2025. The company introduced PrimeScan 2, an upgraded version of its intraoral scanner, which features enhanced speed, usability, and accuracy, designed to improve both the clinical experience and workflow integration.
Another notable development was the European launch of the MIS LYNX implant system under the MIS brand, which received strong initial feedback from clinicians. Additionally, DENTSPLY SIRONAcontinued rolling out DS Core, its digital cloud platform that integrates diagnostics, imaging, and treatment planning across devices. As the first quarter unfolds, investors' focus will be on the early commercial performance of these technologies and how they support procedural growth, particularly in restorative and implant dentistry.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. price-eps-surprise | DENTSPLY SIRONA Inc. Quote
What the Zacks Model Unveils for XRAY
Our proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
XRAY’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -4.92%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +0.86% and a Zacks Rank #2. The company is slated to release first-quarter 2025 results on May 9. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANIP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.32%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 30.6% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.82% and a Zacks Rank #2. The company is slated to release first-quarter fiscal 2025 results on May 7.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 4.94%. The Zacks Consensus Estimate for COR’s fiscal first-quarter EPS is expected to rise 7.1% from the year-ago reported figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +17.37% and a Zacks Rank #3. The company is slated to release first-quarter 2025 results on May 7.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 54.58%.